Baidu
map

王杰军——深刻认识肿瘤治疗:a person in pain not pain in person

2016-06-18 MedSci MedSci原创

第十二届全国癌症康复与姑息医学大会,于2016年6月17日~19日在合肥举行。本届大会的主题是“科学、人文、实践、合作”。梅斯医学作为媒体合作单位采访了大会主席王杰军教授,以下为部分现场报告。 据统计,美国2015年新发肿瘤例数为166万,死亡病例为59万;而2015年中国癌症发病率和死亡率持续上升,根据《2015年中国癌症统计报告》,中国预计有429.2万例新发肿瘤病例和281.4万例死亡

第十二届全国癌症康复与姑息医学大会,于2016年6月17日~19日在合肥举行。本届大会的主题是“科学、人文、实践、合作”。梅斯医学作为媒体合作单位采访了大会主席王杰军教授,以下为部分现场报告。

据统计,美国2015年新发肿瘤例数为166万,死亡病例为59万;而2015年中国癌症发病率和死亡率持续上升,根据《2015年中国癌症统计报告》,中国预计有429.2万例新发肿瘤病例和281.4万例死亡病例。沉重的数据告诉我们,大多数癌症仍不可治愈,且癌症逐渐向慢性病转化,因此应加大肿瘤的姑息治疗宣传教育,规范肿瘤姑息治疗,最大程度的让患者和家属获益。

王杰军教授耐心的讲解姑息治疗应贯穿癌症治疗全程

a person in pain  not pain in person 

王杰军教授指出,传统治疗从肿瘤患者的诊断到死亡的过程中,临床医生会全力以赴在治疗之初进行根治性治疗(包括根治性手术或放化疗),癌症进入晚期时再进行姑息性的缓解治疗。但在发展中国家,肿瘤早期病人非常少,临床上,大多数肿瘤都是不可治愈性疾病。肿瘤患者的姑息治疗应该是贯穿全程的,包括在诊断时的心理障碍缓解,及晚期临终关怀,甚至死亡后的患者家属关怀。因此,姑息治疗是肿瘤标准治疗的重要方面。

比如,疼痛的治疗首先应理解为一个人患有疼痛,而不是疼痛发生在人身上。人才是治疗的主体,姑息治疗要将人(个体)放在第一位。

人类文明的进步在某个侧面似乎正体现在对每个个体的更大程度的尊重上。而当今医学的发展,尤其是在肿瘤治疗领域,这一趋势表现的尤为突出。大量的研究显示,个体基因及蛋白水平的差异与肿瘤的发生、发展、对治疗的敏感性等均存在着密切的联系。肿瘤的治疗正从传统的同疾则同治的经验模式向量“体”裁“医”的个体化治疗模式转变。这种模式使得疾病的治疗更加注重个体化差异,即更加注重以人为主体的精准、全程、系统化的综合治疗。

随着社会经济水平的发展,人们对精神层面的需求逐渐升高,肿瘤治疗如何在保证“救命”的同时,更大程度的满足患者及家属的精神需求,狭义上来说是在如何以治愈或延长患者生存期为目的的同时,最大程度的改善患者的生活质量。这是临床医生需要不断思考和探索的。这对缓和医患关系也有积极的作用。

好的医生治疗的是疾病,然而伟大的医生治疗的是得病的患者。我们需要治疗得病的“人”,而不仅仅是“病”。

世界癌症宣言的九大目标:强调重视癌症的全程管理和控制、重视康复、姑息和支持治疗、有效的控制癌痛和心理痛苦。通过大量的研究和实践可以看到,姑息治疗≠临终关怀,可以简单理解为支持治疗 和/或 舒缓治疗,更直白的说就是让患者及家属“活的好+尊严辞世”。这就要求姑息治疗不仅仅治疗疾病本身,更要关注患者本人。正如心理社会肿瘤学缔造者吉米.霍兰教所讲:医学不仅仅是装在瓶子里的药!希望医学界通过更加系统、全面、客观、科学的姑息治疗,为我们中国肿瘤患者带来的“私人定制”的抗癌及姑息治疗方案。

总结:大多数肿瘤仍属于不可自愈性疾病,且肿瘤逐渐向慢性病发展,肿瘤患者及家属都有着很大的心理负担,如何保证延长患者生存期的同时,改善生活质量是临床医生需要不断努力的。因此肿瘤患者的姑息治疗至关重要。临床医生应贯彻以人为本的治疗思路,让患者和家属最大程度的获益。

专家介绍:

王杰军,教授,医学博士,博士研究生导师,毕业于第二军医大学,现任长征医院肿瘤科主任。中国人民解放军肿瘤专业委员会主任委员、中华医学会上海分会肿瘤专科委员会前任主任委员、中国生命关怀协会副会长、上海癌症康复与姑息治疗专业委员会主任委员、中国癌症康复与姑息治疗专业委员会候任主任委员、上海市防癌抗癌事业发展基金会副理事长、中国临床肿瘤协作中心(CSCO)常务委员、中华医学会疼痛学分会常务委员、国家药品监督管理局药物审评委员会委员、解放军肿瘤研究所副所长、上海综合性医院肿瘤防治专业委员会主任委员等。

梅斯医学

梅斯医学(MedSci)是中国领先的医生互联网平台,拥有超过120万注册医生用户,主要从事临床研究、医生继续教育和培训,以及智慧医疗服务,旨在推动和加速临床医生的职业成长,改善医疗质量。

更多全国癌症康复与姑息医学大会内容,请关注梅斯医学APP


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2017-03-21 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-23 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-20 jetleo

    说的好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 沉心多思

    好文章,值得学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 ljh0111

    重视癌症的全程管理和控制

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 乐奕11

    领悟了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2027229, encodeId=1d6f202e229c9, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Fri Oct 07 09:53:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726126, encodeId=d1451e2612675, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 21 21:53:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878160, encodeId=389418e8160b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 23 22:53:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90573, encodeId=e637905e359, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Jun 20 00:30:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304027, encodeId=b5b4130402eed, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sun Jun 19 21:53:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90352, encodeId=934b903528c, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 17:58:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90337, encodeId=66fc9033e9b, content=重视癌症的全程管理和控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5b11304786, createdName=ljh0111, createdTime=Sat Jun 18 16:59:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90318, encodeId=ae59903184b, content=领悟了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Jun 18 09:39:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90317, encodeId=363a9031e9d, content=理解的很好,表达的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:37:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 huangwukui

    理解的很好,表达的很好

    0

相关资讯

王杰军:肿瘤姑息治疗应贯穿癌症治疗的全过程

为了交流国内外临床肿瘤姑息治疗领域的实践经验和科研成果,积极推动我国姑息治疗学科的健康迅速发展,由中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC)主办,CSCO、《临床肿瘤学杂志》社和安徽医科大学第一附属医院协办的第十二届全国癌症康复与姑息医学大会,于2016年6月17日~19日在合肥举行。 本届大会的主题是“科学、人文、实践、合作”。梅斯医学作为媒体合作单位采访了大会主席王杰军教授

PCOS 2015:ASCO、AAHPM联合发布肿瘤姑息治疗指导声明

美国临床肿瘤学会(ASCO">ASCO)的肿瘤姑息治疗论坛(Palliative Care in Oncology Symposium 2015,PCOS 2015)将于10月9-10日于美国波士顿召开。PCOS 2015新闻发布会在美东时间10月5日下午12时举行。 在2015年肿瘤姑息治疗论坛(PCOS 2015)上,美国临床肿瘤学会(ASCO)和美国宁养与姑息医学会(AAHPM)将联

王杰军:奋进中的中国肿瘤姑息治疗 ——CRPC中国行癌痛专场郑州站

2016年4月16日,由中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC)主办,羚锐公司承办的CRPC中国行癌痛专场在郑州承办召开,与会的是来自河南、河北、北京等地区的肿瘤治疗专家120多人。 大会主席由CRPC主任委员,上海长征医院的王杰军教授与CRPC常务委员,河南省肿瘤医院罗素霞教授共同担任。 本次会议的前一天正值中国抗癌协会发起的4.15全

Baidu
map
Baidu
map
Baidu
map